Main info

Identifier:

HOVON 27 NHL 94

Sponsor:

HOVON

Included patients:

98

Active sites:

0

(of 12)

12 sites are pending

Title:

Triple High-Dose Chemotherapy with Autologous Stem Cell Support as First Line Treatment for High-Risk Non Hodgkin?s Lymphoma: A Phase II Study.

Timeline

Flow

Details

Phase:

Prospective Phase II study

Monitoring Type:

Objectives:

Eligibility

Inclusion Criteria:

• Biopsy proven NHL of high or intermediate histology according to the Working Formulation.
• No prior treatment.
• Belonging to the high risk group.
• Ages between 15 and 65 years.

Exclusion Criteria:

• HIV positivity.
• Prior malignancy, except skin (non-melanoma) or cervix carcinoma stage I.
• Severe major organ dysfunction or metabolic disease.
• Inadequate liver or renal function, unless due to NHL.
• WHO performance > 2.
• Inability to give informed consent.
• CNS involvement of NHL.
• Acute lymphoblastic leukemia.
• WF groups I,J, stage I non-bulky and LDH < 1.5 x normal.

Participating Sites

= Active hospitals

= Inactive hospitals